Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) is set to present its groundbreaking obstructive sleep apnea (OSA) treatment technology at the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Conference. CEO Olivier Taelman will deliver a corporate presentation on March 17, 2025, at 8:40am ET, highlighting the company's innovative approach to addressing one of healthcare's most prevalent conditions.
Revolutionary Neuromodulation Technology
At the heart of Nyxoah's innovation is the Genio® system, a distinctive battery-free hypoglossal neuromodulation device that represents a significant advancement in OSA treatment. The device's unique design requires only a single incision under the chin for insertion and is controlled by a wearable component, offering a less invasive alternative to traditional OSA therapies.
Clinical Success and Regulatory Achievements
The company's commitment to clinical excellence has yielded impressive results through multiple studies. Following the successful BLAST OSA study, Genio® secured European CE Mark approval in 2019. More recently, the positive outcomes from the BETTER SLEEP study led to an expanded CE Mark approval, notably including patients with Complete Concentric Collapse (CCC) – a patient population currently contraindicated in competitive therapies.
Market Position and Future Prospects
Nyxoah has established a strong market presence through successful dual listings on Euronext Brussels (September 2020) and NASDAQ (July 2021). The company's latest milestone, positive results from the DREAM IDE pivotal study, positions them favorably for potential FDA approval and subsequent U.S. market entry.
Addressing a Global Health Challenge
The company's focus on OSA addresses a significant global health burden, with approximately one billion people affected worldwide. Through their innovative approach to neuromodulation therapy, Nyxoah aims to provide more effective treatment options for this widespread condition, potentially transforming the standard of care for OSA patients.
